Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders

Reviews in Clinical and Experimental Hematology

Volumn 5, Issue 2, 2001, Pages 135-146

  Slavin, Shimon ^a   Nagler, Arnon ^a   Aker, Mehmet ^a   Shapira, Michael Y ^a   Cividalli, Gabriel ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOIMMUNITY; CANCER; CELL COMPARTMENTALIZATION; CHRONIC MYELOID LEUKEMIA; ERADICATION THERAPY; GRAFT VERSUS HOST REACTION; GRANULOMATOUS INFLAMMATION; HUMAN; IMMUNOREACTIVITY; LEUKEMIA CELL; LYMPHOCYTE TRANSFUSION; REVIEW; STEM CELL TRANSPLANTATION;

CRITICAL ILLNESS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; MYELOABLATIVE AGONISTS; NEOPLASMS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035382484     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2001.00036.x     Document Type: Review

References (35)

1. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
2. Graft-versus-leukemia reactions after bone marrow transplantation
3. Graft-versus-leukemia reactions in humans
4. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation
5. Total lymphoid irradiation
6. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation
7. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man
8. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
9. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
10. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
11. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
12. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
13. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies
14. Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes
15. Eradication of murine leukemia with histoin-compatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI)
16. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
17. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
18. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
19. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
20. Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma
21. The effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma
22. Fludarabine based protocol for BMT in Fanconi anemia
23. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for a malignant lymphoma
24. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant
25. A new non-myeloablative protocol using fludarabine and low-dose TBI in preparation for allogeneic blood stem cell transplantation for high risk patients with malignant and non-malignant disorders
26. Matched unrelated bone marrow transplantation (BMT) using a non-myeloablative conditioning regimen
27. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
28. Engraftment and induction of GVL with fludarabine based non-ablative preparative regimens in patients with chronic lymphocytic leukemia and lymphoma
29. 'Mini-allografts': Ongoing trials in humans
30. Treatment of myeloid leukemias with non-myeloablative stem cell transplantation: Accomplishments and future goals
31. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB x NZW) F1 hybrids with spontaneous lymphosarcoma
32. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
33. Cancer immunotherapy with alloreactive lymphocytes
34. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia
35. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis